Mitchell L Shiffman

Summary

Publications

  1. doi request reprint Management of acute hepatitis B
    Mitchell L Shiffman
    Bon Secours Health System, Liver Institute of Virginia, Richmond, VA, USA
    Clin Liver Dis 14:75-91; viii-ix. 2010
  2. doi request reprint Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C
    M L Shiffman
    McGuire Research Institute, McGuire Veterans Administration Medical Center, Richmond, VA, USA
    Aliment Pharmacol Ther 31:969-78. 2010
  3. pmc Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Gastroenterology 137:1986-94. 2009
  4. ncbi request reprint A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
    Nevin Yilmaz
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Transpl 13:975-83. 2007
  5. ncbi request reprint Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation
    R Todd Stravitz
    Section of Hepatology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Liver Transpl 10:850-8. 2004
  6. ncbi request reprint Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
  7. ncbi request reprint Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Hepatology 46:371-9. 2007
  8. doi request reprint Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation
    R Todd Stravitz
    Section of Hepatology, Division of Gastroenterology, Hume Lee Transplant Center, Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Liver Int 32:1138-45. 2012
  9. ncbi request reprint Adult living donor versus deceased donor liver transplantation: a 6-year single center experience
    Daniel G Maluf
    Division of Transplantation, Department of Surgery, Virginia Commonwealth University Health System, Richmon, VA, USA
    Am J Transplant 5:149-56. 2005
  10. ncbi request reprint Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298 0341, USA
    Am J Gastroenterol 99:866-72. 2004

Collaborators

Detail Information

Publications58

  1. doi request reprint Management of acute hepatitis B
    Mitchell L Shiffman
    Bon Secours Health System, Liver Institute of Virginia, Richmond, VA, USA
    Clin Liver Dis 14:75-91; viii-ix. 2010
    ..However, the use of an oral anti-HBV agent is not unreasonable to use in a patient who is developing acute liver failure from severe acute HBV...
  2. doi request reprint Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C
    M L Shiffman
    McGuire Research Institute, McGuire Veterans Administration Medical Center, Richmond, VA, USA
    Aliment Pharmacol Ther 31:969-78. 2010
    ..Increased apoptosis and activated caspases are present in these patients. PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases...
  3. pmc Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Gastroenterology 137:1986-94. 2009
    ..This analysis was performed to determine whether suppressing HCV RNA during the trial was associated with a reduction in clinical outcomes...
  4. ncbi request reprint A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
    Nevin Yilmaz
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Transpl 13:975-83. 2007
    ..However, complications associated with sepsis, not recurrent cirrhosis, was the most common cause of death in patients with recurrent HCV and this was similar in patients with or without advanced fibrosis...
  5. ncbi request reprint Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation
    R Todd Stravitz
    Section of Hepatology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Liver Transpl 10:850-8. 2004
    ..In conclusion, interferon treatment of recurrent hepatitis C does not consistently improve histologic disease after virologic response, and it may increase the risk of allograft rejection...
  6. ncbi request reprint Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  7. ncbi request reprint Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Hepatology 46:371-9. 2007
    ..SVR was significantly greater (P < 0.05) in group 3 patients (49%). This resulted from a significant decline (P < 0.05) in relapse rate; only 8% versus 38% for groups 1 and 2...
  8. doi request reprint Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation
    R Todd Stravitz
    Section of Hepatology, Division of Gastroenterology, Hume Lee Transplant Center, Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Liver Int 32:1138-45. 2012
    ..However, the use of HBIg has many disadvantages...
  9. ncbi request reprint Adult living donor versus deceased donor liver transplantation: a 6-year single center experience
    Daniel G Maluf
    Division of Transplantation, Department of Surgery, Virginia Commonwealth University Health System, Richmon, VA, USA
    Am J Transplant 5:149-56. 2005
    ..Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx...
  10. ncbi request reprint Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298 0341, USA
    Am J Gastroenterol 99:866-72. 2004
    ..The present study describes our experience of treating HCV in the inmate population of the Virginia Department of Corrections...
  11. pmc Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples
    Richard K Sterling
    Virginia Commonwealth University Health System, Richmond, USA
    Clin Gastroenterol Hepatol 8:1070-6. 2010
    ..However, no studies have directly compared fibrosis progression by paired liver biopsy between patients infected with HIV and HCV versus those infected with only HCV...
  12. ncbi request reprint Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C
    Arun J Sanyal
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, VA 23298 0341, USA
    Hepatology 43:682-9. 2006
    ..It is also associated with a lower rate of development of ascites, hyperbilirubinemia, and hepatocellular carcinoma. However, cardiovascular mortality is greater in patients with NASH...
  13. ncbi request reprint Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
    Curr Gastroenterol Rep 8:46-52. 2006
    ....
  14. ncbi request reprint Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years
    Nevin Yilmaz
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Int 28:72-8. 2008
    ..Maintaining a serum anti-HB surface level above a minimum arbitrary titre of 200 pg/mL did not appear to be necessary for effective HBIG prophylaxis...
  15. ncbi request reprint Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
    Cleve Clin J Med 71:S13-6. 2004
    ..Long-term maintenance therapy with pegylated interferon is currently being evaluated in nonresponders with advanced fibrosis and cirrhosis. Its use should be considered investigational at this time...
  16. ncbi request reprint Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    N Engl J Med 357:124-34. 2007
    ..We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin...
  17. ncbi request reprint Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival
    Daniel G Maluf
    Department of Surgery, Hume Lee Transplant Center, Virginia Commonwealth University, Richmond, VA 23298 0248, USA
    Transplantation 83:853-7. 2007
    ..This study aimed to evaluate the outcomes of our HCV+/end-stage renal disease (ESRD) patient population based on the therapeutic option including KTx or continuation in dialysis...
  18. doi request reprint Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes
    Jenny O Smith
    Hepatology Section and Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Liver Transpl 15:273-9. 2009
    ..Efforts to modify those factors that contribute to PLOS may reduce this event, improve survival, and reduce OLT-associated costs...
  19. ncbi request reprint Management of patients with chronic hepatitis C virus infection and previous nonresponse
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Rev Gastroenterol Disord 4:S22-30. 2004
    ..This article reviews the factors to consider when assessing nonresponders for additional therapy and options for patients with continued nonresponse...
  20. doi request reprint Effect of hyponatraemia on outcomes following orthotopic liver transplantation
    William A Hackworth
    Liver Transplant Program, Hume Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Liver Int 29:1071-7. 2009
    ..Aims: To assess impact of pretransplant hyponatraemia on post-transplant outcomes...
  21. doi request reprint Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23226, USA
    Liver Int 33:105-10. 2013
    ..The factors which should be considered when deciding whether to treat a patient with HCV and mild fibrosis with the current SOC now, or to delay treatment until less toxic and/or more effective therapy is available is discussed...
  22. doi request reprint A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis
    Jonathan T Hlivko
    Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0341, USA
    Clin Gastroenterol Hepatol 6:1036-40. 2008
    ..Although this regimen achieves remission in approximately 80%, some patients are intolerant or do not respond. Mycophenolate mofetil (MMF) is a potent immunosuppressant. However, its utility in AIH is not well-defined...
  23. ncbi request reprint Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA
    Am J Gastroenterol 102:761-6. 2007
    ..These results suggest that African Americans have a global defect in their ability to eradicate HCV infection following treatment with interferon and ribavirin which transcends across all genotypes...
  24. ncbi request reprint Chronic hepatitis C in patients with persistently normal alanine transaminase levels
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA, and Hospital General de Valencia, Spain
    Clin Gastroenterol Hepatol 4:645-52. 2006
    ..We compared characteristics of chronic hepatitis C patients with patients with normal and elevated ALT levels using data from 3 randomized phase III trials of peginterferon alfa-2a (40 kDa)...
  25. ncbi request reprint Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection
    Richard K Sterling
    Virginia Commonwealth University, Medical College of Virginia, Richmond, USA
    Clin Gastroenterol Hepatol 2:432-9. 2004
    ....
  26. doi request reprint Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23662, USA
    Liver Int 32:54-60. 2012
    ..The latter is highly dependent upon IFN sensitivity and the IL28B genotype...
  27. doi request reprint Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA mshiffma vcu edu
    Oncology 78:11-6. 2010
    ..Based upon the available data, there appears to be no rationale for utilizing Peg-IFN maintenance therapy in patients with cirrhosis and this approach does not reduce the risk of HCC...
  28. ncbi request reprint The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome
    Onpan Cheung
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Richmond, VA 23298, USA
    Hepatology 46:1091-100. 2007
    ..However, DCL is most strongly associated with severity of steatohepatitis. WC and BMI added modestly to the contribution of DCL to severity of nonalcoholic steatohepatitis...
  29. pmc Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection
    Richard K Sterling
    Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0341, USA
    Hepatology 47:1118-27. 2008
    ..Although we did identify genotype 3, increased BMI, and diabetes as risk factors, we found no independent association with antiretroviral therapy...
  30. doi request reprint Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome
    Richard Todd Stravitz
    Section of Hepatology, Hume Lee Transplant Center of Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Am J Med 121:119-26. 2008
    ..We hypothesized that the quality of surveillance for hepatocellular carcinoma influences prognosis by affecting access to liver transplantation...
  31. ncbi request reprint Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Division of Surgical Pathology, Virginia Commonwealth University Medical Center, Richmond, VA, 23298, USA
    Liver Transpl 10:1248-55. 2004
    ..9, compared with 59% with fibrosis and a mean score of.9 after LDLT. In conclusion, these data strongly suggest that fibrosis progression from recurrent HCV is not more severe in patients after LDLT...
  32. ncbi request reprint Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  33. doi request reprint Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C
    Onpan Cheung
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    J Clin Gastroenterol 45:76-82. 2011
    ..However, the impact of mild-moderate alcohol use on the severity of liver fibrosis is unclear...
  34. ncbi request reprint Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation
    Robert A Fisher
    Department of Surgery, Division of Transplantation, Virginia Commonwealth University Health Systems at Medical College of Virginia Hospitals, Richmond, 23298 0254, USA
    Clin Transplant 18:463-72. 2004
    ..The goal of this study was to evaluate a multidrug approach that would reduce both early and long-term morbidity related to immunosuppression while maintaining an acceptable freedom from rejection...
  35. ncbi request reprint A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Comonwealth University Medical Center, Richmond, VA 23298 0711, USA
    Clin Gastroenterol Hepatol 2:1107-15. 2004
    ....
  36. doi request reprint Treatment of hepatitis C in 2011: what can we expect?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Mary Immaculate Hospital Medical Pavilion suite 313, Newport News, VA 23602, USA
    Curr Gastroenterol Rep 12:70-5. 2010
    ....
  37. doi request reprint Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis
    Erik Seth Kramer
    Department of Epidemiology and Community Health, Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Dig Dis Sci 54:2016-25. 2009
    ....
  38. ncbi request reprint Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response
    Amrita Sethi
    Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
    Clin Liver Dis 9:453-71, vii-viii. 2005
    ..The management of these patients creates a formidable challenge. This article outlines various strategies for patients who have failed to achieve SVR and discusses the merits of different approaches to management...
  39. ncbi request reprint Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome
    Arun J Sanyal
    Department of Pathology, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Am J Gastroenterol 98:2064-71. 2003
    ....
  40. doi request reprint Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Clin Liver Dis 12:487-505, vii. 2008
    ..This review discusses strategies to optimize peginterferon and ribavirin dosing and the impact that growth factors may have on the ability to achieve a sustained virologic response...
  41. ncbi request reprint Use of diagnostic testing for managing hepatitis C virus infection
    Andrea Ferreira-Gonzalez
    Division of Molecular Diagnostics, Department of Pathology, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA
    Semin Liver Dis 24:9-18. 2004
    ..In contrast, changes in serum HCV RNA level are important predictors of virological response to treatment with pegylated interferon and ribavirin...
  42. doi request reprint What future for ribavirin?
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Int 29:68-73. 2009
    ..However, based on the results of clinical trials conducted to date, it is much more likely that peginterferon, not ribavirin, could be expendable...
  43. ncbi request reprint Side effects of medical therapy for chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, 23298, USA
    Ann Hepatol 3:5-10. 2004
    ..Appropriate recognition and management of these side effects will both improve response to therapy and avoid unnecessary morbidity and mortality...
  44. ncbi request reprint Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients
    Mitchell L Shiffman
    Hepatology Section, Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Am J Gastroenterol 99:975-6. 2004
  45. doi request reprint Interferon-free regimens: the near future, the likely and the not so likely
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Newport News, VA 23602, USA
    Clin Liver Dis 15:665-75. 2011
    ..These observations are used to speculate as to whether an all-oral antiviral cocktail could "cure" HCV in the near future...
  46. ncbi request reprint Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298, USA
    Am J Gastroenterol 98:1159-66. 2003
    ..The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection...
  47. pmc Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus
    M Fernanda Sábato
    Molecular Diagnostics Laboratory, Department of Pathology, Virginia Commonwealth University, Richmond, Virginia 23298 0248, USA
    J Clin Microbiol 45:2529-36. 2007
    ..19 log(10) IU/ml. Our study demonstrates that Roche RUO-MPLC and Abbott ASR-Q provided acceptable results and agreed sufficiently with the COBAS Amplicor HCV Monitor v2.0...
  48. ncbi request reprint Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C
    R Todd Stravitz
    Section of Hepatology, Division of Gastroenterology and the Division of Hematology Oncology, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298 0341, USA
    Am J Gastroenterol 100:1415-9. 2005
    ..PRCA caused by the development of erythropoietin antibodies is a potentially life-threatening complication of administering epoetin alfa to prevent the anemia associated with antiviral therapy in patients with chronic hepatitis C...
  49. doi request reprint Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    J Clin Pharmacol 51:1293-301. 2011
    ..Therefore, the results do not support daily ADV dosing using a liquid suspension over the current strategy of adjustment of the ADV dosing interval in patients with impaired renal function...
  50. ncbi request reprint Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, Richmond, VA 23298, USA
    Liver Transpl 9:S14-20. 2003
    ..4. Achieving a sustained virological response after treatment with interferon, with or without ribavirin, is associated with a reduced risk for the development of cirrhosis and HCC and prolonged survival...
  51. ncbi request reprint Controversies in the management of hepatitis C virus infection after liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Liver Transpl 9:1129-44. 2003
    ....
  52. pmc Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost
    Patrick G Northup
    Department of Medicine, University of Virginia, Charlottesville, VA, USA
    Liver Transpl 15:148-62. 2009
    ..The addition of LDLT to a standard waiting list DDLT program is effective at improving recipient survival and preventing waiting list deaths but at a greater cost...
  53. doi request reprint Role and support for hepatologists at liver transplant programs in the United States
    Mitchell L Shiffman
    Hepatology Section and Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Transpl 14:1092-9. 2008
    ..The current shortage of transplant hepatologists is likely to increase if appropriate support mechanisms are not implemented...
  54. ncbi request reprint Benign recurrent intrahepatic cholestasis
    Velimir A Luketic
    Hepatology Section, Virginia Commonwealth University Health System, West Hospital, 14th Floor, 1200 East Broad Street, Richmond, VA 23219, USA
    Clin Liver Dis 8:133-49, vii. 2004
    ..Therapy is supportive and aimed at relieving pruritus and other complications of severe cholestasis until the episode resolves spontaneously...
  55. ncbi request reprint Chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA
    Semin Liver Dis 24:1-2. 2004
  56. ncbi request reprint A balancing view: We cannot do it alone
    Mitchell L Shiffman
    Chief, Hepatology Section, Medical Director, Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Am J Gastroenterol 102:1841-3. 2007
  57. ncbi request reprint Retreatment of patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Medical College of Virginia, Richmond, VA 23298, USA
    Hepatology 36:S128-34. 2002
    ..These results help to focus retreatment with peginterferon and ribavirin on subsets of patients who are most likely to benefit...
  58. ncbi request reprint Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values
    Pouneh Mofrad
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
    Hepatology 37:1286-92. 2003
    ....